Sara Najafi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sara Najafi has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Ina Oehme
Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
2 shared publications - Sara Raji
Persian Cohort Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publications Arash Akahavan Rezayat
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Infectious Disease Research Center, AJA University of Medical Sciences, Tehran, Iran
1 shared publicationBrent Kreider
BioMed Valley Discoveries Inc., Kansas City, MO
1 shared publication- Caroline Alvares
Department of Haematology, Cardiff Experimental Cancer Medicine Centre, University of Cardiff, Cardiff, UK
1 shared publication Charlotte Gatzweiler
Hopp Children’s Cancer Center Heidelberg (KiTZ)/German Cancer Research Center (DKFZ), Heidelberg, Germany
1 shared publication
Latest Publications
- Open Access
- 17 November 2025
- Published by Federal Medical Biological Agency in Extreme Medicine
- Vol. 27 (4) , 525-535
Safety and efficacy of small interfering RNA agents (lumasiran) in therapy for primary hyperoxaluria type 1: A systematic review
Introduction. Primary hyperoxaluria type 1 (PH1) is an inherited disorder characterized by excessive oxalate production in the liver, leading to hyperoxaluria, kidney stone formation, nephrocalcinosis, and progressive kidney damage. PH1 is caused by mutations in the AGXT gene, whereas types 2 and 3 are associated with mutations in GRHPR and HOGA1, respectively. Lumasiran, an RNA interference (RNAi)-based therapeutic agent, targets the HAO1 gene (hydroxyacid oxidase 1), thus reducing the levels of glycolate oxidase. This action results in decreased hepatic oxalate production. Objective. Evaluation of the efficacy, safety, and clinical use of lumasiran in adults and children with genetically confirmed primary hyperoxaluria type 1. Materials and methods . The systematic review was conducted in accordance with the PRISMA 2020 guidelines. A comprehensive literature search was performed across four databases (PubMed, Scopus, Web of Science, and EMBASE). Studies were selected based on their focus on the use of lumasiran in pediatric or adult patients with genetically confirmed primary hyperoxaluria type 1. The quality and risk of bias were assessed using the Joanna Briggs Institute (JBI) critical appraisal tools. The final analysis included 11 studies: two randomized controlled trials, two prospective single-arm studies, one case series (involving five patients), and six individual clinical case reports involving both pediatric and adult populations. Discussion. Lumasiran treatment was found to lead to a significant reduction in urinary oxalate (UOx) levels (approximately 60–75%) and plasma oxalate (POx) levels (approximately 30–60%). Patients across all age groups, from infants to adults, exhibited markedly stabilized or improved renal function, alongside reduced progression of nephrocalcinosis. Lumasiran demonstrated a favorable safety profile, with the most common adverse events being mild injection-site reactions. No serious treatment-related adverse events requiring discontinuation of therapy were reported. Conclusions . By suppressing glycolate oxidase expression, lumasiran has consistently demonstrated significant efficacy in reducing oxalate levels. However, there exist differences in therapeutic approaches for adult patients and infants, as well as in treatment effects based on baseline renal function and dosing regimens. Both pediatric and adult populations showed substantial improvement and stabilization of renal function, although infants and patients with advanced chronic kidney disease required dose adjustments. Studies also revealed a greater variability in renal outcomes, particularly regarding the progression of nephrocalcinosis. Although additional large-scale long-term studies are needed, our findings indicate that lumasiran may impede the progression of kidney disease and potentially reduce or delay the need for kidney transplantation in PH1.
- 17 November 2025
- Published by Federal Medical Biological Agency in Extreme Medicine
- Vol. 27 (4) , 525-535
Open AccessSafety and efficacy of small interfering RNA agents (lumasiran) in therapy for primary hyperoxaluria type 1: A systematic review
Introduction. Primary hyperoxaluria type 1 (PH1) is an inherited disorder characterized by excessive oxalate production in the liver, leading to hyperoxaluria, kidney stone formation, nephrocalcinosis, and progressive kidney damage. PH1 is caused by mutations in the AGXT gene, whereas types 2 and 3 are associated with mutations in GRHPR and HOGA1, respectively. Lumasiran, an RNA interference (RNAi)-based therapeutic agent, targets the HAO1 gene (hydroxyacid oxidase 1), thus reducing the levels of glycolate oxidase. This action results in decreased hepatic oxalate production. Objective. Evaluation of the efficacy, safety, and clinical use of lumasiran in adults and children with genetically confirmed primary hyperoxaluria type 1. Materials and methods . The systematic review was conducted in accordance with the PRISMA 2020 guidelines. A comprehensive literature search was performed across four databases (PubMed, Scopus, Web of Science, and EMBASE). Studies were selected based on their focus on the use of lumasiran in pediatric or adult patients with genetically confirmed primary hyperoxaluria type 1. The quality and risk of bias were assessed using the Joanna Briggs Institute (JBI) critical appraisal tools. The final analysis included 11 studies: two randomized controlled trials, two prospective single-arm studies, one case series (involving five patients), and six individual clinical case reports involving both pediatric and adult populations. Discussion. Lumasiran treatment was found to lead to a significant reduction in urinary oxalate (UOx) levels (approximately 60–75%) and plasma oxalate (POx) levels (approximately 30–60%). Patients across all age groups, from infants to adults, exhibited markedly stabilized or improved renal function, alongside reduced progression of nephrocalcinosis. Lumasiran demonstrated a favorable safety profile, with the most common adverse events being mild injection-site reactions. No serious treatment-related adverse events requiring discontinuation of therapy were reported. Conclusions . By suppressing glycolate oxidase expression, lumasiran has consistently demonstrated significant efficacy in reducing oxalate levels. However, there exist differences in therapeutic approaches for adult patients and infants, as well as in treatment effects based on baseline renal function and dosing regimens. Both pediatric and adult populations showed substantial improvement and stabilization of renal function, although infants and patients with advanced chronic kidney disease required dose adjustments. Studies also revealed a greater variability in renal outcomes, particularly regarding the progression of nephrocalcinosis. Although additional large-scale long-term studies are needed, our findings indicate that lumasiran may impede the progression of kidney disease and potentially reduce or delay the need for kidney transplantation in PH1.
- Open Access
- 17 September 2024
- Published by Springer Nature in Leukemia
- Vol. 38 (12) , 2561-2572
Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins
Internal tandem duplications in the FMS-like tyrosine kinase-3 (FLT3-ITD) are common mutations in acute myeloid leukemia (AML). Proteolysis-targeting chimeras (PROTACs) that induce proteasomal degradation of mutated FLT3 emerge as innovative pharmacological approach. Molecular mechanisms that control targeted proteolysis beyond the ubiquitin-proteasome-system are undefined and PROTACs are the only known type of FLT3 degraders. We report that the von-Hippel-Lindau ubiquitin-ligase based FLT3 PROTAC MA49 (melotinib-49) and the FLT3 hydrophobic tagging molecule MA50 (halotinib-50) reduce endoplasmic reticulum-associated, oncogenic FLT3-ITD but spare FLT3. Nanomolar doses of MA49 and MA50 induce apoptosis of human leukemic cell lines and primary AML blasts with FLT3-ITD (p < 0.05-0.0001), but not of primary hematopoietic stem cells and differentiated immune cells, FLT3 wild-type cells, retinal cells, and c-KIT-dependent cells. In vivo activity of MA49 against FLT3-ITD-positive leukemia cells is verified in a Danio rerio model. The degrader-induced loss of FLT3-ITD involves the pro-apoptotic BH3-only protein BIM and a previously unidentified degrader-induced depletion of protein-folding chaperones. The expression levels of HSP90 and HSP110 correlate with reduced AML patient survival (p < 0.1) and HSP90, HSP110, and BIM are linked to the expression of FLT3 in primary AML cells (p < 0.01). HSP90 suppresses degrader-induced FLT3-ITD elimination and thereby establishes a mechanistically defined feed-back circuit.
- 17 September 2024
- Published by Springer Nature in Leukemia
- Vol. 38 (12) , 2561-2572
Open AccessSelective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins
Internal tandem duplications in the FMS-like tyrosine kinase-3 (FLT3-ITD) are common mutations in acute myeloid leukemia (AML). Proteolysis-targeting chimeras (PROTACs) that induce proteasomal degradation of mutated FLT3 emerge as innovative pharmacological approach. Molecular mechanisms that control targeted proteolysis beyond the ubiquitin-proteasome-system are undefined and PROTACs are the only known type of FLT3 degraders. We report that the von-Hippel-Lindau ubiquitin-ligase based FLT3 PROTAC MA49 (melotinib-49) and the FLT3 hydrophobic tagging molecule MA50 (halotinib-50) reduce endoplasmic reticulum-associated, oncogenic FLT3-ITD but spare FLT3. Nanomolar doses of MA49 and MA50 induce apoptosis of human leukemic cell lines and primary AML blasts with FLT3-ITD (p < 0.05-0.0001), but not of primary hematopoietic stem cells and differentiated immune cells, FLT3 wild-type cells, retinal cells, and c-KIT-dependent cells. In vivo activity of MA49 against FLT3-ITD-positive leukemia cells is verified in a Danio rerio model. The degrader-induced loss of FLT3-ITD involves the pro-apoptotic BH3-only protein BIM and a previously unidentified degrader-induced depletion of protein-folding chaperones. The expression levels of HSP90 and HSP110 correlate with reduced AML patient survival (p < 0.1) and HSP90, HSP110, and BIM are linked to the expression of FLT3 in primary AML cells (p < 0.01). HSP90 suppresses degrader-induced FLT3-ITD elimination and thereby establishes a mechanistically defined feed-back circuit.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5221
Abstract 5221: The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics
Ulixertinib (BVD-523) is a well-tolerated, orally delivered, catalytic ERK1/2 inhibitor, which has shown promising responses in adult patients with mitogen-activated protein kinase (MAPK)-driven solid tumors. Pediatric low grade gliomas (pLGGs) are the most common pediatric brain tumors, with the most frequent driving alterations (KIAA:BRAF fusion, BRAF V600E mutation) occurring in the MAPK pathway. To investigate the anti-tumoral activity of ulixertinib in pLGG, cell lines recapitulating both main MAPK alterations were used: DKFZ-BT66 (pilocytic astrocytoma; KIAA:BRAF fusion) and BT40 (pleomorphic xanthoastrocytoma; BRAF V600E mutation and CDKN2A/B deletion). The potential synergism of combinations with MEK inhibitors, senolytics, and chemotherapy was investigated in vitro using metabolic activity and MAPK activity assays. The most promising combinations were validated in vitro by analysis of viable, dead, and apoptotic cells through high-content microscopy. The most clinically relevant combinations were further validated in vivo: 1) in two zebrafish embryo models (respectively, BT40 and DKFZ-BT66 yolk sac injection) and 2) in NSG mice (BT40 orthotopic PDX) including in vivo pharmacokinetic and -dynamic analyses. Our data demonstrate ulixertinib’s ability to inhibit MAPK pathway activity in all used models. Ulixertinib treatment reduced cell viability in the BRAF V600E mutated cell line at a remarkably low concentration of 62.7 nM (compared to other cell lines’ IC50 from the Genomics of Drug Sensitivity in Cancer database). In vivo pharmacokinetic and -dynamic analyses showed good penetrance of the drug into mouse brain tissue, with concentrations above the in vitro IC50 and reduction of MAPK activity as assessed by Western blot. Furthermore, ulixertinib treatment slowed tumor growth and significantly increased survival in NSG mice with orthotopic BT40 xenografts. Ulixertinib showed indications for anti-proliferative synergy in vitro, according to the Loewe and Bliss independence models, in combination with MEK inhibitors (trametinib, binimetinib) or senolytics (navitoclax, A1331852). Combinations with chemotherapy (carboplatin, vinblastine) were at most additive. Indications for synergy with binimetinib and navitoclax were confirmed in the zebrafish embryo xenograft models for both MAPK-altered backgrounds. The combination of ulixertinib with navitoclax was further investigated in the BT40 PDX mouse model, where tumor growth and survival were comparable to ulixertinib monotherapy. In conclusion, our data indicate a strong potential for ulixertinib as a clinically relevant therapeutic option for the treatment of pLGG to be further investigated in upcoming clinical trials. Potential synergism with MEK inhibitors and senolytics was noted and warrants further investigation. Citation Format: Romain Sigaud, Lisa Rösch, Charlotte Gatzweiler, Julia Benzel, Laura von Soosten, Heike Peterziel, Sara Najafi, Simay Ayhan, Nina Hofmann, Kathrin I. Förster, Jürgen Burhenne, Rémi Longuespée, Cornelis M. van Tilburg, David T. Jones, Stefan M. Pfister, Deborah Knoerzer, Brent Kreider, Max Sauter, Kristian W. Pajtler, Marc Zuckermann, Ina Oehme, Olaf Witt, Till Milde. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5221.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5221
Open AccessAbstract 5221: The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics
Ulixertinib (BVD-523) is a well-tolerated, orally delivered, catalytic ERK1/2 inhibitor, which has shown promising responses in adult patients with mitogen-activated protein kinase (MAPK)-driven solid tumors. Pediatric low grade gliomas (pLGGs) are the most common pediatric brain tumors, with the most frequent driving alterations (KIAA:BRAF fusion, BRAF V600E mutation) occurring in the MAPK pathway. To investigate the anti-tumoral activity of ulixertinib in pLGG, cell lines recapitulating both main MAPK alterations were used: DKFZ-BT66 (pilocytic astrocytoma; KIAA:BRAF fusion) and BT40 (pleomorphic xanthoastrocytoma; BRAF V600E mutation and CDKN2A/B deletion). The potential synergism of combinations with MEK inhibitors, senolytics, and chemotherapy was investigated in vitro using metabolic activity and MAPK activity assays. The most promising combinations were validated in vitro by analysis of viable, dead, and apoptotic cells through high-content microscopy. The most clinically relevant combinations were further validated in vivo: 1) in two zebrafish embryo models (respectively, BT40 and DKFZ-BT66 yolk sac injection) and 2) in NSG mice (BT40 orthotopic PDX) including in vivo pharmacokinetic and -dynamic analyses. Our data demonstrate ulixertinib’s ability to inhibit MAPK pathway activity in all used models. Ulixertinib treatment reduced cell viability in the BRAF V600E mutated cell line at a remarkably low concentration of 62.7 nM (compared to other cell lines’ IC50 from the Genomics of Drug Sensitivity in Cancer database). In vivo pharmacokinetic and -dynamic analyses showed good penetrance of the drug into mouse brain tissue, with concentrations above the in vitro IC50 and reduction of MAPK activity as assessed by Western blot. Furthermore, ulixertinib treatment slowed tumor growth and significantly increased survival in NSG mice with orthotopic BT40 xenografts. Ulixertinib showed indications for anti-proliferative synergy in vitro, according to the Loewe and Bliss independence models, in combination with MEK inhibitors (trametinib, binimetinib) or senolytics (navitoclax, A1331852). Combinations with chemotherapy (carboplatin, vinblastine) were at most additive. Indications for synergy with binimetinib and navitoclax were confirmed in the zebrafish embryo xenograft models for both MAPK-altered backgrounds. The combination of ulixertinib with navitoclax was further investigated in the BT40 PDX mouse model, where tumor growth and survival were comparable to ulixertinib monotherapy. In conclusion, our data indicate a strong potential for ulixertinib as a clinically relevant therapeutic option for the treatment of pLGG to be further investigated in upcoming clinical trials. Potential synergism with MEK inhibitors and senolytics was noted and warrants further investigation. Citation Format: Romain Sigaud, Lisa Rösch, Charlotte Gatzweiler, Julia Benzel, Laura von Soosten, Heike Peterziel, Sara Najafi, Simay Ayhan, Nina Hofmann, Kathrin I. Förster, Jürgen Burhenne, Rémi Longuespée, Cornelis M. van Tilburg, David T. Jones, Stefan M. Pfister, Deborah Knoerzer, Brent Kreider, Max Sauter, Kristian W. Pajtler, Marc Zuckermann, Ina Oehme, Olaf Witt, Till Milde. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5221.
- 1 January 2022
- Published by Elsevier in Public Health
- Vol. 202, 131-138
Incidence of infectious diseases after earthquakes: a systematic review and meta-analysis
- 1 January 2022
- Published by Elsevier in Public Health
- Vol. 202, 131-138
Incidence of infectious diseases after earthquakes: a systematic review and meta-analysis
- Open Access
- 20 May 2021
- Published by DoNotEdit in Iranian Red Crescent Medical Journal
- Vol. 23 (6)
Meningitis induced by severe acute respiratory syndrome coronavirus 2: A case report
Introduction: Coronavirus disease 2019 (COVID-19) emerged in December 2019 in China and caused a catastrophic pandemic in 2020. Significant manifestations of COVID-19 are related to the respiratory system; however, other organs, such as the brain and heart, can also be involved. Case presentation: A 44-year-old-male was hospitalized in our referral emergency center due to being febrile and confused. He experienced five episodes of convulsion in the hospital. Within a day, the respiratory symptoms developed. The polymerase chain reaction of cerebrospinal fluid (CSF) was positive for COVID-19. The analysis of CSF and findings of chest computed tomography scan revealed that the case was infected with meningitis induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and pneumonia. Conclusions: It has been reported that neurological symptoms of COVID-19 can appear earlier than other symptoms. To the best of our knowledge, few articles have represented COVID-induced meningitis. This case study reported the first case of meningitis induced by SARS-CoV-2 in Iran
- 20 May 2021
- Published by DoNotEdit in Iranian Red Crescent Medical Journal
- Vol. 23 (6)
Open AccessMeningitis induced by severe acute respiratory syndrome coronavirus 2: A case report
Introduction: Coronavirus disease 2019 (COVID-19) emerged in December 2019 in China and caused a catastrophic pandemic in 2020. Significant manifestations of COVID-19 are related to the respiratory system; however, other organs, such as the brain and heart, can also be involved. Case presentation: A 44-year-old-male was hospitalized in our referral emergency center due to being febrile and confused. He experienced five episodes of convulsion in the hospital. Within a day, the respiratory symptoms developed. The polymerase chain reaction of cerebrospinal fluid (CSF) was positive for COVID-19. The analysis of CSF and findings of chest computed tomography scan revealed that the case was infected with meningitis induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and pneumonia. Conclusions: It has been reported that neurological symptoms of COVID-19 can appear earlier than other symptoms. To the best of our knowledge, few articles have represented COVID-induced meningitis. This case study reported the first case of meningitis induced by SARS-CoV-2 in Iran
- Open Access
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Hypoxia‐Induced miR‐210 Overexpression Promotes the Differentiation of Human‐Induced Pluripotent Stem Cells to Hepatocyte‐Like Cells on Random Nanofiber Poly‐L‐Lactic Acid/Poly (ε‐Caprolactone) Scaffolds
An alternative treatment to liver transplantation includes the use of differentiated stem cells. Hypoxia has been shown to endow human‐induced pluripotent stem cells (hiPSCs) with enhanced hepatic differentiation. We have investigated a new strategy for hepatocyte differentiation from hiPSCs using a three‐step differentiation protocol with lentiviral overexpression of hypoxia‐microRNA‐210 of cells grown on a hybrid scaffold. We analyzed the transduction of the miR‐210 lentiviral and definitive endoderm and pluripotency gene markers, including SRY‐box 17 (SOX17), forkhead box A2 (FOXA2), and octamer‐binding transcription factor 4 (OCT‐4) by Real‐Time PCR and fluorescent microscope. The scanning electron microscopy (SEM) examined the 3D cell morphological changes. Immunocytochemistry staining was used together with assays for aspartate aminotransferase, alanine aminotransferase, and urea secretion to analyze hepatocyte biomarkers and functional markers consisting of α‐fetoprotein (AFP), low‐density lipoprotein (LDL) uptake, fat accumulation, and glycogen. The flow cytometry analyzed the generation of reactive oxygen species (ROS). Compared to cells transfected with the blank lentiviral vectors as a control, overexpressing miR‐210 was at higher levels in hiPSCs. The expression of endodermal genes and glycogen synthesis significantly increased in the differentiated lentiviral miR‐210 cells without any differences regarding lipid storage level. Additionally, cells containing miR‐210 showed a greater expression of ALB, LDL, AST, ALT, urea, and insignificant lower AFP and ROS levels after 18 days. However, SEM showed no significant differences between cells under the differentiation process and controls. In conclusion, the differentiation of hiPSCs to hepatocyte‐like cells under hypoxia miR‐210 may be a suitable method for cell therapy and regenerative medicine.
- 1 January 2021
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2021 (1)
Open AccessHypoxia‐Induced miR‐210 Overexpression Promotes the Differentiation of Human‐Induced Pluripotent Stem Cells to Hepatocyte‐Like Cells on Random Nanofiber Poly‐L‐Lactic Acid/Poly (ε‐Caprolactone) Scaffolds
An alternative treatment to liver transplantation includes the use of differentiated stem cells. Hypoxia has been shown to endow human‐induced pluripotent stem cells (hiPSCs) with enhanced hepatic differentiation. We have investigated a new strategy for hepatocyte differentiation from hiPSCs using a three‐step differentiation protocol with lentiviral overexpression of hypoxia‐microRNA‐210 of cells grown on a hybrid scaffold. We analyzed the transduction of the miR‐210 lentiviral and definitive endoderm and pluripotency gene markers, including SRY‐box 17 (SOX17), forkhead box A2 (FOXA2), and octamer‐binding transcription factor 4 (OCT‐4) by Real‐Time PCR and fluorescent microscope. The scanning electron microscopy (SEM) examined the 3D cell morphological changes. Immunocytochemistry staining was used together with assays for aspartate aminotransferase, alanine aminotransferase, and urea secretion to analyze hepatocyte biomarkers and functional markers consisting of α‐fetoprotein (AFP), low‐density lipoprotein (LDL) uptake, fat accumulation, and glycogen. The flow cytometry analyzed the generation of reactive oxygen species (ROS). Compared to cells transfected with the blank lentiviral vectors as a control, overexpressing miR‐210 was at higher levels in hiPSCs. The expression of endodermal genes and glycogen synthesis significantly increased in the differentiated lentiviral miR‐210 cells without any differences regarding lipid storage level. Additionally, cells containing miR‐210 showed a greater expression of ALB, LDL, AST, ALT, urea, and insignificant lower AFP and ROS levels after 18 days. However, SEM showed no significant differences between cells under the differentiation process and controls. In conclusion, the differentiation of hiPSCs to hepatocyte‐like cells under hypoxia miR‐210 may be a suitable method for cell therapy and regenerative medicine.